Transposon Therapeutics
Novel NRTIs, PKR
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companies
C-9DIE
Novel NRTIs, PKR
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This snapshot does not present an explicit company mission, belief statement, or theory; it mainly says the website is coming soon and highlights clinical study information related to Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis or Frontotemporal Dementia with C9ORF72 mutation, implying a focus on those neurodegenerative conditions rather than a clearly stated ideological or scientific position.
SourceTransposon Therapeutics states that its mission is to develop innovative treatments for LINE-1-associated neurodegenerative disease. The company presents the view that abnormal activation of human-specific LINE-1 retrotransposons contributes to neurodegeneration, because disease-linked proteins such as tau and TDP-43 can increase LINE-1 expression and trigger a cascade leading to neuronal dysfunction and death. Based on that belief, it is developing inhibitors of LINE-1 reverse transcriptase and other mediators of LINE-1 pathology, including PKR inhibitors, as treatments for neurodegenerative and aging-related diseases.
SourceTransposon Therapeutics states that human-specific LINE-1 retrotransposons can become abnormally active in neurodegenerative disease, and that disease-linked proteins such as tau and TDP-43 can increase LINE-1 expression, triggering a cascade that leads to neuronal dysfunction and death. The company says it is developing treatments that inhibit LINE-1 reverse transcriptase and other mediators of LINE-1 pathology, including PKR, as a therapeutic approach for neurodegenerative diseases.
Source